Next Page
What is INQOVI?
With INQOVI,
there’s no
place like home
INQOVI® (decitabine and cedazuridine) tablets—the first and only oral hypomethylating agent (HMA) for the treatment of myelodysplastic syndromes (MDS), including CMML. With INQOVI, patients can take their therapy in the convenience and comfort of their own home or wherever they are.1
CMML=chronic myelomonocytic leukemia.
Who is INQOVI for?
INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including1:
- previously treated and untreated, de novo and secondary MDS with the following French‑American‑British subtypes:
- refractory anemia
- refractory anemia with ringed sideroblasts
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia (CMML)
- intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups
National Comprehensive Cancer Network® (NCCN®)2
Oral decitabine and cedazuridine (DEC-C) can be considered as a substitution for intravenous decitabine for treatment of intermediate- or high-risk MDS based on Category 2A* evidence in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes.
- Do not substitute decitabine and cedazuridine (INQOVI) for an IV decitabine product within a cycle1
*Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.1.2021. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed September 15, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.